PE-22-28 vs Selank
Side-by-side comparison of PE-22-28 and Selank: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
PE-22-28
Selank
PE-22-28
PE-22-28 is a synthetic seven-amino-acid peptide (sequence PAGASRLLLLTGEIDLP derivative, commonly truncated to PE-22-28 as shorthand for "position 22-28" within the parent humanin-family sequence) that was designed as an…
Lowest listed price: $54.99 across 1 listing
Full PE-22-28 profileSelank
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro, 750 Da molecular weight) developed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences as a synthetic analog of tuftsin…
Lowest listed price: $25.00 across 6 listings
Full Selank profileSide-by-side comparison
| Attribute | PE-22-28 | Selank |
|---|---|---|
| Category | Nootropics | Nootropics |
| Research Stage | Preclinical | Approved (Russia, as anxiolytic and nootropic medication) |
| Mechanism of Action | PE-22-28 is a synthetic 7-amino-acid peptide (sequence GVSWGLR) and a shortened analog of spadin. Its proposed mechanism is inhibition of the TREK-1 (TWIK-related K+) channel, a two-pore-domain potassium channel (K2P2.1 / KCNK2) implicated in mood regulation.… | Primary Mechanism: Multi-System Neurochemical Modulation Selank does not have a single clean receptor-binding mechanism. Unlike benzodiazepines (GABA-A positive allosteric modulators), SSRIs (serotonin reuptake inhibition), or buspirone (5-HT1A partial… |
| Half-Life | Not characterized in humans. As a small 7-amino-acid peptide a short plasma half-life is expected; in mice the parent peptide spadin lost antidepressant activity by about 7 hours after a single dose, while modified analogs (e.g., G/A-PE 22-28) extended the behavioral effect to roughly 21-23 hours [PMID:28955242]. | ~2-3 minutes plasma half-life (functional anxiolytic and nootropic effects persist 12-24 hours due to gene expression and neurotransmitter modulation) |
| Typical Dose Range | 250-2000 mcg subcutaneous per dose (empirical research-chemical community range; no clinically validated human dose exists; effective preclinical rodent doses were far lower, ~3 mcg/kg). | 250-750 mcg intranasal daily (0.15% solution: 2-3 drops per nostril 2-3x daily); typical course is 14-21 days |
| Dosing Frequency | Once daily or every other day (research-chemical community protocols; no validated clinical dosing schedule). | Intranasal 1–3 times daily |
| Administration | — | Intranasal |
| Side Effects | No human side-effect data exist for PE-22-28 because it has never been tested in people. What can be said comes from rodent studies of PE-22-28, spadin and their analogs, plus general considerations for injected research peptides. In the preclinical work, the… | Overall Safety Profile Selank has one of the best safety profiles in the anxiolytic space. Over 15+ years of Russian clinical use and research, the compound has been associated with essentially no serious adverse events at therapeutic doses. This compares… |
| Molecular Weight | 773.9 g/mol | 751.9 Da |
| Common Vial Sizes | — | 5mg, 10mg |
Price tracking
Price History
5 data points- OF
- Half Nattys
- Ion Peptide
- BHG Labs
PE-22-28: potential benefits
- Antidepressant-like effects in rodent models of depression (preclinical only)
- Potent, selective inhibition of the TREK-1 (K2P2.1) potassium channel (IC50 ~0.12 nM)
- Rapid-onset (~4-day) antidepressant profile in animals, unlike the multi-week lag of SSRIs
- Increased hippocampal neurogenesis in mice
- Increased cortical synaptogenesis (PSD-95) and BDNF expression in preclinical studies
- No human-validated benefits; not approved for any use (research use only)
Selank: potential benefits
- Anxiolytic effects comparable to benzodiazepines but without sedation or dependence in Russian clinical trials (PMID: 18454096)
- Positive allosteric modulation of brain GABA receptors through a non-benzodiazepine binding site (PMID: 30255741)
- Immunomodulation via Th1/Th2 cytokine balance and IL-6 regulation in patients with anxiety-asthenic disorders (PMID: 18577961)
- Cognitive and memory support linked to BDNF upregulation in the hippocampus in preclinical models (PMID: 18841804)
- Modulation of the endogenous enkephalin-opioid system supporting mood and stress tolerance (PMID: 22550852)
- Anti-inflammatory and adaptogenic effects through normalization of stress-induced cytokine dysregulation
- Non-addictive anxiolytic profile - no tolerance, withdrawal, or dependence reported across years of Russian clinical use
Frequently asked
What's the difference between PE-22-28 and Selank?
PE-22-28 is a nootropics that pe-22-28 is a synthetic 7-amino-acid peptide (sequence gvswglr) and a shortened analog of spadin. its proposed mechanism is inhibition of the trek-1 (twik-related k+) channel, a…. Selank is a nootropics that primary mechanism: multi-system neurochemical modulation selank does not have a single clean receptor-binding mechanism. unlike benzodiazepines (gaba-a positive allosteric…. The two differ in mechanism, half-life (Not characterized in humans. As a small 7-amino-acid peptide a short plasma half-life is expected; in mice the parent peptide spadin lost antidepressant activity by about 7 hours after a single dose, while modified analogs (e.g., G/A-PE 22-28) extended the behavioral effect to roughly 21-23 hours [PMID:28955242]. vs ~2-3 minutes plasma half-life (functional anxiolytic and nootropic effects persist 12-24 hours due to gene expression and neurotransmitter modulation)), and typical dose range.
Which has the longer half-life, PE-22-28 or Selank?
PE-22-28 has a half-life of Not characterized in humans. As a small 7-amino-acid peptide a short plasma half-life is expected; in mice the parent peptide spadin lost antidepressant activity by about 7 hours after a single dose, while modified analogs (e.g., G/A-PE 22-28) extended the behavioral effect to roughly 21-23 hours [PMID:28955242].. Selank has a half-life of ~2-3 minutes plasma half-life (functional anxiolytic and nootropic effects persist 12-24 hours due to gene expression and neurotransmitter modulation). Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, PE-22-28 or Selank?
Lowest listed price on BodyHackGuide: PE-22-28 from $54.99, Selank from $25.00. Prices are pulled from the vendor listings tracked on BHG and change frequently. See the compare tables on each compound page for the current set of offers.
Can you stack PE-22-28 and Selank?
Stacking depends on mechanism overlap, safety profile, and goals. PE-22-28 and Selank should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy PE-22-28 or Selank
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. Every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.